BPA for tarpeyo
Active Awarded Last action
- Contract number
- 36E79723A0013
- Awardee
-
Calliditas Therapeutics US Inc. UEI MAZGQDV5PK59
- Awarding agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Task orders
- 0
Award facts
- Opportunity
-
- VA797P12Q0002 Solicitation number
- Last date to order 89% complete
- IDV ceiling
- $1,750,000.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
Calliditas Therapeutics US Inc. (UEI: MAZGQDV5PK59) has been awarded a single-award Blanket Purchase Agreement valued at $1.75 million by the Department of Veterans Affairs' National Acquisition Center, effective from April 4, 2023, through April 3, 2027. This contract authorizes the procurement of TARPEYO, a pharmaceutical product indicated for the treatment of primary immunoglobulin A nephropathy in adult patients with uncontrolled proteinuria. The BPA is structured under the Federal Supply Schedule's Pharmaceuticals and Drugs schedule (FSS-61-IB) and designates Calliditas Therapeutics US Inc. as the sole approved supplier of this specialized medication to Veterans Affairs medical facilities nationwide. No set-aside provisions were employed in this award, reflecting the specialized and limited-source nature of the pharmaceutical product being procured.
The contract supports the Department of Veterans Affairs' healthcare delivery mission by ensuring reliable access to TARPEYO for eligible veteran patients diagnosed with primary immunoglobulin A nephropathy across the VA's integrated service networks. Delivery orders issued under this BPA are firm fixed-price arrangements, with historical order values ranging from approximately $10,600 to $382,900 per delivery order. The structure of this indefinite delivery vehicle provides the VA with a streamlined procurement mechanism for managing ongoing pharmaceutical supply requirements while maintaining cost certainty and supplier continuity for this critical therapeutic intervention addressing a serious renal condition affecting the veteran population.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 36E79723A0013?
36E79723A0013 was awarded to Calliditas Therapeutics US Inc. by National Acquisition Center (Headquarters) on April 4, 2023.
How much is contract 36E79723A0013 worth?
36E79723A0013's own ceiling is $1,750,000.
Who can order from contract 36E79723A0013?
36E79723A0013 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.
Is contract 36E79723A0013 under another contract?
Yes. 36E79723A0013 is a blanket purchase agreement under 36F79722D0153, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36E79723A0013 competed?
The extent of competition for 36E79723A0013 was full and open competition. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV